125 related articles for article (PubMed ID: 28581463)
21. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of using the Multinational Association of Supportive Care in Cancer Antiemesis Tool for assessment of chemotherapy-induced nausea and vomiting at the Tom Baker Cancer Centre.
Warr JK; Chambers CR; Cusano FL; Cuthbert CA; Mah MS
J Oncol Pharm Pract; 2015 Oct; 21(5):348-57. PubMed ID: 24938292
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
24. Olanzapine as a rescue antiemetic in hematopoietic stem cell transplant.
Monson T; Greer D; Kreikemeier E; Liewer S
J Oncol Pharm Pract; 2020 Jun; 26(4):918-922. PubMed ID: 31635549
[TBL] [Abstract][Full Text] [Related]
25. Delayed Chemotherapy-Induced Nausea and Vomiting in the Hematology Population: A Review of the Literature.
Gonella S; Di Giulio P
Clin J Oncol Nurs; 2015 Aug; 19(4):438-43. PubMed ID: 26207708
[TBL] [Abstract][Full Text] [Related]
26. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
27. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
Schwartzberg LS; Jacobs P; Matsouka P; Azevedo W; Pinto A
Crit Rev Oncol Hematol; 2012 Jul; 83(1):59-70. PubMed ID: 22321726
[TBL] [Abstract][Full Text] [Related]
28. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life.
Ballatori E; Roila F; Ruggeri B; Betti M; Sarti S; Soru G; Cruciani G; Di Maio M; Andrea B; Deuson RR
Support Care Cancer; 2007 Feb; 15(2):179-85. PubMed ID: 16941136
[TBL] [Abstract][Full Text] [Related]
29. Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update.
Patel P; Robinson PD; Devine KA; Positano K; Cohen M; Gibson P; Holdsworth M; Phillips R; Spinelli D; Thackray J; van de Wetering M; Woods D; Cabral S; Sung L; Dupuis LL
Pediatr Blood Cancer; 2021 May; 68(5):e28947. PubMed ID: 33686754
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
Schwartzberg L; Morrow G; Balu S; Craver C; Gayle J; Cox D
Curr Med Res Opin; 2011 Aug; 27(8):1613-22. PubMed ID: 21696263
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
[TBL] [Abstract][Full Text] [Related]
32. Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.
Dranitsaris G; Bouganim N; Milano C; Vandermeer L; Dent S; Wheatley-Price P; Laporte J; Oxborough KA; Clemons M
J Support Oncol; 2013 Mar; 11(1):14-21. PubMed ID: 22763232
[TBL] [Abstract][Full Text] [Related]
33. Safety of Dexamethasone for Nausea and Vomiting Prophylaxis in Children Receiving Hematopoietic Stem Cell Transplantation.
Paw Cho Sing E; Schechter T; Ali M; Sung L; Dupuis LL
J Pediatr Hematol Oncol; 2018 Jul; 40(5):e278-e282. PubMed ID: 29702540
[TBL] [Abstract][Full Text] [Related]
34. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
35. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.
Okamoto S; Takahashi S; Tanosaki R; Sakamaki H; Onozawa Y; Oh H; Miyawaki S; Kimura Y; Toyama K; Ikeda Y; Asano S
Bone Marrow Transplant; 1996 May; 17(5):679-83. PubMed ID: 8733681
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings.
Cohen L; de Moor CA; Eisenberg P; Ming EE; Hu H
Support Care Cancer; 2007 May; 15(5):497-503. PubMed ID: 17103197
[TBL] [Abstract][Full Text] [Related]
37. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT.
Musso M; Scalone R; Crescimanno A; Bonanno V; Polizzi V; Porretto F; Bianchini C; Perrone T
Bone Marrow Transplant; 2010 Jan; 45(1):123-7. PubMed ID: 19483762
[TBL] [Abstract][Full Text] [Related]
38. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Tan J; Wang S; Liang X; Li CC; Zhang J; Zhao Z; Kong XR; Deng X; Peng L; Yang C
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28941006
[TBL] [Abstract][Full Text] [Related]
39. Control of Nausea and Vomiting in Patients with Colorectal Cancer Receiving Chemotherapy with Moderate Emetic Risk.
Suzuki A; Kobayashi R; Fujii H; Iihara H; Takahashi T; Yoshida K; Itoh Y
Anticancer Res; 2016 Dec; 36(12):6527-6533. PubMed ID: 27919978
[TBL] [Abstract][Full Text] [Related]
40. Delayed nausea and vomiting from carboplatin doublet chemotherapy.
Waqar SN; Mann J; Baggstrom MQ; Waqar MA; Chitneni P; Williams K; Gao F; Morgensztern D; Govindan R
Acta Oncol; 2016 Jun; 55(6):700-4. PubMed ID: 27145068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
